|
Atherosclerosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In total, nine SNPs of RAGE were analyzed in individuals with and without type 2 diabetes in CODAM: a cohort study of diabetes and atherosclerosis, Maastricht.
|
18079485 |
2008 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study, therefore, identifies SAA as a potential new uremic toxin involved in uremia-related atherosclerosis through interaction with RAGE.
|
26988587 |
2016 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Multiligand receptor for advanced glycation end products (RAGE), osteoprotegerin, and Golgb1 genes may be implicated in atherosclerosis and vascular diseases.
|
26664786 |
2015 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
RAGE does not seem to play a major role in the development of NASH or atherosclerosis in a hyperlipidemic mouse model.
|
30323247 |
2018 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Receptor for advanced glycation end products (RAGE) and its multiple ligands have been implicated in the pathogenesis of accelerated atherosclerosis; however, little is known about the effects of RAGE activation on vascular calcification.
|
21512281 |
2011 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Except one, all studies showed suppressing effects for RSV on the production of AGEs or receptor for advanced glycation end products (RAGE) and its detrimental consequences including oxidative stress, inflammatory response, cellular immune reactions, insulin response, and atherosclerosis.
|
31185146 |
2019 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis.
|
17761193 |
2007 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results demonstrated a potential role of monocyte adhesion, chemotaxis, and macrophage polarization in the development cardiovascular diseases induced by IH and identified that RAGE could be a promising therapeutic target to prevent atherosclerosis in patients with OSA.
|
30402462 |
2018 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Blockade of receptor for advanced glycation end products (RAGE) attenuates vascular oxidative stress and development of atherosclerosis.
|
28826719 |
2017 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
For example, soluble RAGE reduces murine atherosclerosis and vascular inflammation.
|
26515415 |
2015 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
There is accumulating evidence that the AGEs-RAGE interaction plays an important role in accelerated atherosclerosis in diabetes.
|
31378770 |
2019 |
|
Atherosclerosis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, compared with the corresponding wild-type genotype, the rs2269422 single-nucleotide polymorphism of RAGE was associated with the susceptibility of patients with CAD to atherosclerosis.
|
30783474 |
2019 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Receptor for advanced glycation end products (RAGE) is a cell-surface molecule member of the immunoglobulin superfamily and thought to play a critical role in diabetic atherosclerosis.
|
24078092 |
2013 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Proinflammatory cell activation via the receptor for advanced glycation end products (RAGE) pathway may play a central pathogenetic role in atherosclerosis.
|
21472666 |
2011 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The receptor for advanced glycation end products (RAGE) is thought to play a critical role in diabetic atherosclerosis.
|
15547674 |
2004 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Advanced glycosylation end product-specific receptor (AGER) signaling has been implicated in atherosclerosis.
|
26226616 |
2015 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
These AGE molecules bind to their respective receptors called the receptor for advanced glycation end products (RAGE) and initiate several aberrant signaling pathways leading to onset of diseases such as diabetes, Alzheimer's, atherosclerosis, heart failure and cancer.
|
28546110 |
2018 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Strategies to reduce the ligation of AGEs to their receptors such as agents which reduce AGE accumulation, soluble RAGE which acts as a competitive antagonist to the binding of AGEs to RAGE and genetic deletions of RAGE appear to attenuate diabetes associated atherosclerosis.
|
18473849 |
2008 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
We also outline novel treatments targeting the AGE-RAGE axis and specific Nox isoforms, which hold great promise in attenuating the development of diabetes-associated atherosclerosis and diabetic nephropathy.
|
26323666 |
2015 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Atorvastatin improves plaque stability in diabetic atherosclerosis through the RAGE pathway.
|
29509268 |
2018 |
|
Atherosclerosis
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
High mobility group box 1 (HMGB1) and receptor for advanced glycation end products (RAGE) cause the activation of intracellular signaling, gene expression, and production of inflammatory cytokines and have been linked to many inflammatory disease states such as diabetes mellitus and atherosclerosis.
|
28092162 |
2017 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Studies in rodent models of diabetes suggest that blockade or genetic modification of RAGE suppress diabetes-associated progression of atherosclerosis, exaggerated neointimal expansion consequent to acute arterial injury, and cardiac dysfunction.
|
16305050 |
2004 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Therefore these results suggested that first, RAGE activation may be important in mediating AngII-induced atherogenesis, and second, AngII activation is a major pathway in the development of atherosclerosis.
|
23936343 |
2013 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Receptor for advanced glycation end products (RAGE), a member of cell adhesion molecules, plays an important role in chronic inflammation and atherosclerosis.
|
28535664 |
2017 |
|
Atherosclerosis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The expression of RAGE is up-regulated in atherosclerotic plaques of diabetic animals, and the augmentation of atherosclerosis in diabetic mice is inhibited by the competition of RAGE.
|
18089449 |
2008 |